# US 11,679,146 B2 · Compositions and methods for treating pancreatitis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,679,146 B2
- Document ID: US11679146B2
- Status: Granted
- Kind: B2
- Application number: 15/734,461
- Filed: 2019-06-04
- Published: 2021-07-15
- Granted: 2023-06-20
- Earliest claimed: 2018-06-05
- Assignees: Anji Pharmaceuticals Inc.
- Applicants: Anji Pharmaceuticals Inc.
- Inventors: Charles D. Meyers; Brian K. Hubbard; Michael H. Serrano-Wu
- Web page: https://patentgrep.com/patent/US11679146B2

## CPC

- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 38/4813: {Exopeptidases (3.4.11. to 3.4.19)}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 38/482: {Serine endopeptidases (3.4.21)}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12Y 304/21061: Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12Y 304/11001: Leucyl aminopeptidase (3.4.11.1)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present disclosure provides methods related to inhibiting or treating pancreatitis in a subject in need thereof, which include the use of a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor. The disclosed PCSK9 inhibitors and compositions including them can be used for treatment, inhibition, or prevention of pancreatitis in a subject. Treatment methods can include administering to the subject a therapeutically effective amount of a PCSK9 inhibitor.

## Claims

### Claim 1

A method of treating acute pancreatitis or chronic pancreatitis in a subject in need thereof, the method comprising administering to the subject a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor, wherein the acute pancreatitis is not caused by an infection,
wherein the PCSK9 inhibitor is AMG145 (Evolocumab), 1D05-IgG2, SAR236553/REGN727 (Alirocumab), RN-316 (Bococizumab), LGT209, LY3015014 (Frovocimab), or RG7652.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method treats acute pancreatitis.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject is human.

### Claim 4

A method of treating acute pancreatitis or chronic pancreatitis in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor, wherein the acute pancreatitis is not caused by an infection,
wherein the PCSK9 inhibitor is AMG145 (Evolocumab), 1D05-IgG2, SAR236553/REGN727 (Alirocumab), RN-316 (Bococizumab), LGT209, LY3015014 (Frovocimab), or RG7652.

### Claim 5 (depends on 4)

The method of claim 4, wherein the method treats acute pancreatitis.

### Claim 6 (depends on 4)

The method of claim 4, wherein the subject is human.